Editas reports Q4 net loss of $18.9M; Vertex license deal provides cash runway into 2026

Editas Medicine, Inc.

2023-FY EPS reported -$2.02 revenue$78,123,000

Q4 net loss $18.9M ($0.23 per share) vs $60.7M ($0.88) in Q4 2022; revenue boosted by Vertex license.
Cash $427.1M as of Dec 31, 2023; with Vertex license payments, runway expected into 2026.
FDA aligns that RUBY trial is single Phase 1/2/3 to support BLA; adolescent cohort enrollment initiated.
Entered license agreement with Vertex for Cas9 for ex vivo SCD/beta thal; $50M contingent upfront plus annual fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.